WHWK Whitehawk Therapeutics, Inc.
$3.46▲ +3.90%
Healthcare
Other
Volume 362.3K
Avg Volume (10D) 335.0K
Key Metrics & Fundamentals
Market Cap
$197.25M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.97 - 5.50
% vs 50 MA
-11.81%
% vs 200 MA
-9.75%
RSI-14
49.9
MACD Histogram
+0.0600
Beta (1Y vs SPY)
1.63
Free Cash Flow
-$14.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.10M
COGS
$0
Operating Exp
$18.11M
Operating Income
-$18.11M
EBIT
-$18.11M
Pretax Income
-$16.64M
Net Income
-$16.64M
EPS (Diluted)
-0.20
Price & Volume History
Loading chart…
Recent News
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
PR Newswire · Oct 7, 2026 7:03 AM ET
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
PR Newswire · Oct 1, 2026 8:00 AM ET
Stifel Initiates Whitehawk Therapeutics at Buy With $9 Price Target
MT Newswires · Oct 1, 2026 6:06 AM ET
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
PR Newswire · Sep 13, 2026 9:30 PM ET
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
PR Newswire · Sep 10, 2026 4:05 PM ET
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
Zacks · Aug 28, 2026 12:00 PM ET
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
Zacks · Aug 26, 2026 9:55 AM ET
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
GlobeNewswire · Aug 13, 2026 4:15 PM ET
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
PR Newswire · Aug 6, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2025
See WHWK's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.